BioDelivery Sciences sues generic competitor to Belbuca

BioDelivery Sciences (NASDAQ:) has filed a patent infringement against Alvogen in response to its filing of an ANDA in the U.S. seeking approval to market a generic version of pain med BELBUCA (buprenorphine) Buccal Film.

BDSI‘s action is standard operating procedure for branded drug makers since it triggers an automatic 30-month stay on potential approval to allow for the legal process to run its course.

Now read:

for full text news in your inbox

Leave a Reply

Your email address will not be published. Required fields are marked *

*